Published in Infect Immun on January 01, 2004
Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin Microbiol Rev (2008) 2.45
Mucosal immunization with iron receptor antigens protects against urinary tract infection. PLoS Pathog (2009) 2.14
Merging mythology and morphology: the multifaceted lifestyle of Proteus mirabilis. Nat Rev Microbiol (2012) 1.48
Probiotics to prevent urinary tract infections: the rationale and evidence. World J Urol (2005) 1.25
Mannose-resistant Proteus-like fimbriae are produced by most Proteus mirabilis strains infecting the urinary tract, dictate the in vivo localization of bacteria, and contribute to biofilm formation. Infect Immun (2004) 1.03
Zinc uptake contributes to motility and provides a competitive advantage to Proteus mirabilis during experimental urinary tract infection. Infect Immun (2010) 1.01
Adhesion, invasion, and agglutination mediated by two trimeric autotransporters in the human uropathogen Proteus mirabilis. Infect Immun (2010) 0.99
Vaccination with proteus toxic agglutinin, a hemolysin-independent cytotoxin in vivo, protects against Proteus mirabilis urinary tract infection. Infect Immun (2008) 0.95
Transcriptome of Proteus mirabilis in the murine urinary tract: virulence and nitrogen assimilation gene expression. Infect Immun (2011) 0.90
Outer membrane antigens of the uropathogen Proteus mirabilis recognized by the humoral response during experimental murine urinary tract infection. Infect Immun (2008) 0.90
Proteus mirabilis and Urinary Tract Infections. Microbiol Spectr (2015) 0.90
Growth inhibition of various Enterobacteriaceae species by the yeast Hansenula anomala during storage of moist cereal grain. Appl Environ Microbiol (2011) 0.86
Transcriptional analysis of the MrpJ network: modulation of diverse virulence-associated genes and direct regulation of mrp fimbrial and flhDC flagellar operons in Proteus mirabilis. Infect Immun (2015) 0.78
Siderophore vaccine conjugates protect against uropathogenic Escherichia coli urinary tract infection. Proc Natl Acad Sci U S A (2016) 0.78
Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections. Microbiol Spectr (2016) 0.77
In silico design of fusion protein of FimH from uropathogenic Escherichia coli and MrpH from Proteus mirabilis against urinary tract infections. Adv Biomed Res (2015) 0.76
Distinct Residues Contribute to Motility Repression and Autoregulation in the Proteus mirabilis Fimbria-Associated Transcriptional Regulator AtfJ. J Bacteriol (2016) 0.76
New aspects of RpoE in uropathogenic Proteus mirabilis. Infect Immun (2014) 0.75
Microbial ureases: significance, regulation, and molecular characterization. Microbiol Rev (1989) 7.03
Ascending, unobstructed urinary tract infection in mice caused by pyelonephritogenic Escherichia coli of human origin. Infect Immun (1983) 5.10
Urease. The primary cause of infection-induced urinary stones. Invest Urol (1976) 4.72
Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science (1997) 4.57
A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters. J Infect Dis (1982) 4.37
Urease-positive bacteriuria and obstruction of long-term urinary catheters. J Clin Microbiol (1987) 3.08
Site of infection in acute urinary-tract infection in general practice. Lancet (1971) 2.77
Swarming and pathogenicity of Proteus mirabilis in the urinary tract. Trends Microbiol (1995) 2.21
Construction of a urease-negative mutant of Proteus mirabilis: analysis of virulence in a mouse model of ascending urinary tract infection. Infect Immun (1990) 2.12
Construction of an MR/P fimbrial mutant of Proteus mirabilis: role in virulence in a mouse model of ascending urinary tract infection. Infect Immun (1994) 1.91
Contribution of Proteus mirabilis urease to persistence, urolithiasis, and acute pyelonephritis in a mouse model of ascending urinary tract infection. Infect Immun (1993) 1.82
Proteus mirabilis flagella and MR/P fimbriae: isolation, purification, N-terminal analysis, and serum antibody response following experimental urinary tract infection. Infect Immun (1991) 1.72
Haemagglutinins and fimbriae of Morganella, Proteus and Providencia. J Med Microbiol (1982) 1.69
Hemagglutinin, urease, and hemolysin production by Proteus mirabilis from clinical sources. J Infect Dis (1990) 1.63
Long-term urethral catheterization increases risk of chronic pyelonephritis and renal inflammation. J Am Geriatr Soc (1994) 1.60
The adhesins and fimbriae of Proteus mirabilis strains associated with high and low affinity for the urinary tract. J Med Microbiol (1983) 1.56
In vivo phase variation of MR/P fimbrial gene expression in Proteus mirabilis infecting the urinary tract. Mol Microbiol (1997) 1.40
Proteus mirabilis MR/P fimbrial operon: genetic organization, nucleotide sequence, and conditions for expression. J Bacteriol (1994) 1.37
Reproductive processes in Proteus cultures. Proc Soc Exp Biol Med (1946) 1.34
Antigenic relationships among type-3 fimbriae of Enterobacteriaceae revealed by immunoelectronmicroscopy. J Med Microbiol (1985) 1.33
Proteus mirabilis fimbriae: construction of an isogenic pmfA mutant and analysis of virulence in a CBA mouse model of ascending urinary tract infection. Infect Immun (1994) 1.30
Economic impact of urolithiasis in the United States. J Urol (1995) 1.24
Visualization of Proteus mirabilis within the matrix of urease-induced bladder stones during experimental urinary tract infection. Infect Immun (2002) 1.22
Proteus mirabilis fimbriae: N-terminal amino acid sequence of a major fimbrial subunit and nucleotide sequences of the genes from two strains. Infect Immun (1993) 1.21
Requirement of MrpH for mannose-resistant Proteus-like fimbria-mediated hemagglutination by Proteus mirabilis. Infect Immun (1999) 1.20
Bacteriology of branched renal calculi and accompanying urinary tract infection. J Urol (1984) 1.16
Identification of MrpI as the sole recombinase that regulates the phase variation of MR/P fimbria, a bladder colonization factor of uropathogenic Proteus mirabilis. Mol Microbiol (2002) 1.14
Proteus morgani is less frequently associated with urinary tract infections than Proteus mirabilis--an explanation. J Med Microbiol (1983) 1.14
Proteus mirabilis fimbriae: identification, isolation, and characterization of a new ambient-temperature fimbria. Infect Immun (1994) 1.12
Evaluation of the discriminatory powers of the Dienes test and ribotyping as typing methods for Proteus mirabilis. J Clin Microbiol (2000) 1.04
Virulence of a Proteus mirabilis ATF isogenic mutant is not impaired in a mouse model of ascending urinary tract infection. FEMS Immunol Med Microbiol (2000) 1.02
Immobilizing antibodies in pyelonephritis. J Immunol (1969) 0.98
Proteus mirabilis mannose-resistant, Proteus-like fimbriae: MrpG is located at the fimbrial tip and is required for fimbrial assembly. Infect Immun (1997) 0.97
Efficacy of a Proteus mirabilis outer membrane protein vaccine in preventing experimental Proteus pyelonephritis in a BALB/c mouse model. Infect Immun (1991) 0.96
Antigenic and immunogenic activity of flagella and fimbriae preparations from uropathogenic Proteus mirabilis. Can J Microbiol (1991) 0.95
The combination of pivampicillin and pivmecillinam versus pivampicillin alone in the treatment of acute pyelonephritis. Scand J Infect Dis (1986) 0.92
Timentin versus piperacillin in the therapy of serious urinary tract infections. Am J Med (1985) 0.89
Evaluation of Proteus mirabilis structural fimbrial proteins as antigens against urinary tract infections. FEMS Immunol Med Microbiol (2003) 0.88
Cefamandole alone and combined with gentamicin or tobramycin in the treatment of acute pyelonephritis. Scand J Infect Dis Suppl (1980) 0.86
Mecillinam versus cephaloridine for the treatment of acute pyelonephritis. Infection (1982) 0.80
Serum immunoglobulin response and protection from homologous challenge by Proteus mirabilis in a mouse model of ascending urinary tract infection. Infect Immun (1999) 0.79
Transcriptome of uropathogenic Escherichia coli during urinary tract infection. Infect Immun (2004) 3.28
Expression of flagella is coincident with uropathogenic Escherichia coli ascension to the upper urinary tract. Proc Natl Acad Sci U S A (2007) 2.56
Defining genomic islands and uropathogen-specific genes in uropathogenic Escherichia coli. J Bacteriol (2007) 2.50
Complete genome sequence of uropathogenic Proteus mirabilis, a master of both adherence and motility. J Bacteriol (2008) 2.47
Mucosal immunization with iron receptor antigens protects against urinary tract infection. PLoS Pathog (2009) 2.14
Host-pathogen interactions in urinary tract infection. Nat Rev Urol (2010) 1.94
Role of motility in the colonization of uropathogenic Escherichia coli in the urinary tract. Infect Immun (2005) 1.80
Proteus mirabilis genes that contribute to pathogenesis of urinary tract infection: identification of 25 signature-tagged mutants attenuated at least 100-fold. Infect Immun (2004) 1.76
Fitness of Escherichia coli during urinary tract infection requires gluconeogenesis and the TCA cycle. PLoS Pathog (2009) 1.67
Escherichia coli global gene expression in urine from women with urinary tract infection. PLoS Pathog (2010) 1.65
Uropathogenic Escherichia coli outer membrane antigens expressed during urinary tract infection. Infect Immun (2007) 1.60
Assessment of virulence of uropathogenic Escherichia coli type 1 fimbrial mutants in which the invertible element is phase-locked on or off. Infect Immun (2002) 1.56
Sat, the secreted autotransporter toxin of uropathogenic Escherichia coli, is a vacuolating cytotoxin for bladder and kidney epithelial cells. Infect Immun (2002) 1.56
Vaxign: the first web-based vaccine design program for reverse vaccinology and applications for vaccine development. J Biomed Biotechnol (2010) 1.55
Quantitative profile of the uropathogenic Escherichia coli outer membrane proteome during growth in human urine. Infect Immun (2007) 1.50
The IrgA homologue adhesin Iha is an Escherichia coli virulence factor in murine urinary tract infection. Infect Immun (2005) 1.49
Merging mythology and morphology: the multifaceted lifestyle of Proteus mirabilis. Nat Rev Microbiol (2012) 1.48
Adaptation to flooding during emergence and seedling growth in rice and weeds, and implications for crop establishment. AoB Plants (2012) 1.48
Waging war against uropathogenic Escherichia coli: winning back the urinary tract. Infect Immun (2009) 1.46
Fimbrial profiles predict virulence of uropathogenic Escherichia coli strains: contribution of ygi and yad fimbriae. Infect Immun (2011) 1.44
Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology (2006) 1.43
Redundancy and specificity of Escherichia coli iron acquisition systems during urinary tract infection. Infect Immun (2011) 1.41
Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem Pharmacol (2009) 1.37
Autotransporter genes pic and tsh are associated with Escherichia coli strains that cause acute pyelonephritis and are expressed during urinary tract infection. Infect Immun (2004) 1.36
Genomic islands of uropathogenic Escherichia coli contribute to virulence. J Bacteriol (2009) 1.34
Coordinate expression of fimbriae in uropathogenic Escherichia coli. Infect Immun (2005) 1.32
Nutritional requirements and antibiotic resistance patterns of Helicobacter species in chemically defined media. J Clin Microbiol (2006) 1.29
Haem acquisition is facilitated by a novel receptor Hma and required by uropathogenic Escherichia coli for kidney infection. Mol Microbiol (2008) 1.25
complex interplay between type 1 fimbrial expression and flagellum-mediated motility of uropathogenic Escherichia coli. J Bacteriol (2007) 1.24
Visualization of Proteus mirabilis within the matrix of urease-induced bladder stones during experimental urinary tract infection. Infect Immun (2002) 1.22
In vivo behavior of a Helicobacter pylori SS1 nixA mutant with reduced urease activity. Infect Immun (2002) 1.21
Transcriptome of swarming Proteus mirabilis. Infect Immun (2010) 1.19
Visualization of Proteus mirabilis morphotypes in the urinary tract: the elongated swarmer cell is rarely observed in ascending urinary tract infection. Infect Immun (2003) 1.16
Escherichia coli physiology and metabolism dictates adaptation to diverse host microenvironments. Curr Opin Microbiol (2011) 1.15
Multicellular bacteria deploy the type VI secretion system to preemptively strike neighboring cells. PLoS Pathog (2013) 1.14
Identification of MrpI as the sole recombinase that regulates the phase variation of MR/P fimbria, a bladder colonization factor of uropathogenic Proteus mirabilis. Mol Microbiol (2002) 1.14
Role of phase variation of type 1 fimbriae in a uropathogenic Escherichia coli cystitis isolate during urinary tract infection. Infect Immun (2006) 1.14
Genome-wide detection of fitness genes in uropathogenic Escherichia coli during systemic infection. PLoS Pathog (2013) 1.10
Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Rev Vaccines (2012) 1.10
Increased incidence of urolithiasis and bacteremia during Proteus mirabilis and Providencia stuartii coinfection due to synergistic induction of urease activity. J Infect Dis (2013) 1.09
The innate immune response to uropathogenic Escherichia coli involves IL-17A in a murine model of urinary tract infection. J Immunol (2010) 1.09
Identification of virulence determinants in uropathogenic Proteus mirabilis using signature-tagged mutagenesis. J Med Microbiol (2008) 1.08
A novel autotransporter of uropathogenic Proteus mirabilis is both a cytotoxin and an agglutinin. Mol Microbiol (2008) 1.07
Dissemination and systemic colonization of uropathogenic Escherichia coli in a murine model of bacteremia. MBio (2010) 1.07
Escherichia coli isolates that carry vat, fyuA, chuA, and yfcV efficiently colonize the urinary tract. Infect Immun (2012) 1.06
Identification and characterization of a novel uropathogenic Escherichia coli-associated fimbrial gene cluster. Infect Immun (2004) 1.06
Adaptation to flooding in upland and lowland ecotypes of Cyperus rotundus, a troublesome sedge weed of rice: tuber morphology and carbohydrate metabolism. Ann Bot (2008) 1.05
Helicobacter pylori HP1512 is a nickel-responsive NikR-regulated outer membrane protein. Infect Immun (2006) 1.04
Multiple genes repress motility in uropathogenic Escherichia coli constitutively expressing type 1 fimbriae. J Bacteriol (2008) 1.04
The type III secretion system of Proteus mirabilis HI4320 does not contribute to virulence in the mouse model of ascending urinary tract infection. J Med Microbiol (2007) 1.04
Presence of putative repeat-in-toxin gene tosA in Escherichia coli predicts successful colonization of the urinary tract. MBio (2011) 1.04
Protease activity, secretion, cell entry, cytotoxicity, and cellular targets of secreted autotransporter toxin of uropathogenic Escherichia coli. Infect Immun (2006) 1.03
The Helicobacter pylori flbA flagellar biosynthesis and regulatory gene is required for motility and virulence and modulates urease of H. pylori and Proteus mirabilis. J Med Microbiol (2002) 1.03
Mannose-resistant Proteus-like fimbriae are produced by most Proteus mirabilis strains infecting the urinary tract, dictate the in vivo localization of bacteria, and contribute to biofilm formation. Infect Immun (2004) 1.03
Zinc uptake contributes to motility and provides a competitive advantage to Proteus mirabilis during experimental urinary tract infection. Infect Immun (2010) 1.01
Detection and mutation of a luxS-encoded autoinducer in Proteus mirabilis. Microbiology (2002) 1.01
PapX, a P fimbrial operon-encoded inhibitor of motility in uropathogenic Escherichia coli. Infect Immun (2008) 1.00
Assessing urgency in interstitial cystitis/painful bladder syndrome. Urology (2007) 1.00
The broadly conserved regulator PhoP links pathogen virulence and membrane potential in Escherichia coli. Mol Microbiol (2011) 0.99
Adhesion, invasion, and agglutination mediated by two trimeric autotransporters in the human uropathogen Proteus mirabilis. Infect Immun (2010) 0.99
Role of the K2 capsule in Escherichia coli urinary tract infection and serum resistance. J Infect Dis (2009) 0.98
Urease of enterohemorrhagic Escherichia coli: evidence for regulation by fur and a trans-acting factor. Infect Immun (2002) 0.98
Determination of target sequence bound by PapX, repressor of bacterial motility, in flhD promoter using systematic evolution of ligands by exponential enrichment (SELEX) and high throughput sequencing. J Biol Chem (2011) 0.96
Vaccines for Proteus mirabilis in urinary tract infection. Int J Antimicrob Agents (2002) 0.96
Repression of motility during fimbrial expression: identification of 14 mrpJ gene paralogues in Proteus mirabilis. Mol Microbiol (2008) 0.96
PhoU enhances the ability of extraintestinal pathogenic Escherichia coli strain CFT073 to colonize the murine urinary tract. Microbiology (2006) 0.95
FdeC, a novel broadly conserved Escherichia coli adhesin eliciting protection against urinary tract infections. MBio (2012) 0.95
Vaccination with proteus toxic agglutinin, a hemolysin-independent cytotoxin in vivo, protects against Proteus mirabilis urinary tract infection. Infect Immun (2008) 0.95
Kinetics of uropathogenic Escherichia coli metapopulation movement during urinary tract infection. MBio (2012) 0.94
Uropathogenic Escherichia coli Suppresses the host inflammatory response via pathogenicity island genes sisA and sisB. Infect Immun (2009) 0.94